Director

Elizabeth A. Mily has more than 30 years of experience across the healthcare and financial services sectors. She currently serves as a director of Solventum Corporation and Ampersand Biomedicines.

Ms. Mily most recently served as CEO of the T1D Fund, an impact investing fund focused on Type 1 diabetes. Prior to the T1D Fund, she served as Executive Vice President, Strategy & Business Development at Bristol-Myers Squibb, overseeing the company strategy and approach to sourcing external innovation, including all business development, M&A, equity investing and alliance management. Prior to joining BMS, Ms. Mily chaired the Life Science Investment Banking business at Barclays, including coverage of the BioPharma, Life Science Tools and Diagnostics sectors. Prior to Barclays, she served as Senior Vice President, Corporate Strategy and Development at Thermo Fisher Scientific. Ms. Mily began her career at Goldman, Sachs & Co., where she spent 16 years and was ultimately a Managing Director in Healthcare Investment Banking.

Ms. Mily holds a Master of Science in Foreign Service from Georgetown University and a Bachelor of Arts in German Literature and European History from the Ohio State University. She was a Fulbright scholar to the Universities of Cologne and Hamburg, Germany.